Evidence map›Paper›PMID 38148602›Full record

ArticleCancer medicine2024

Improved outcomes of localized diffuse large B-cell lymphoma at the Waldeyer ring in comparison to the sinonasal area in the rituximab era.

Wei-Li Ma, Ruey-Long Hong, Pei-Jen Lou, Ming Yao, Shang-Ju Wu, Chung-Wu Lin, Chun-Wei Wang, Chin-Hao Chang, Ann-Lii Cheng, Sung-Hsin Kuo

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Wei-Li MaDepartment of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.ORCID 0000-0002-6840-2976
Ruey-Long HongDepartment of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.
Pei-Jen LouDepartment of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.
Ming YaoDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.
Shang-Ju WuDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.
Chung-Wu LinDepartment of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.ORCID 0000-0001-5042-0503
Chun-Wei WangDepartment of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.
Chin-Hao ChangDepartment of Medical Research, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.
Ann-Lii ChengDepartment of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.
Sung-Hsin KuoDepartment of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.ORCID 0000-0003-0054-887X
National Taiwan University · TWNational Taiwan University Hospital · TW

Funding

National Science and Technology Council, Taiwan Number 110-2314-B-002-219-MY3National Science and Technology Council, Taiwan Number 111-2314-B-002-010-National Science and Technology Council, Taiwan Number 111-2811-B-002-095-National Science and Technology Council, Taiwan Number 112-2314-B-002-156-National Taiwan University Hospital Number 112-S0215
6 · The paper itself

Abstract

backgroundDiffuse large B-cell lymphoma (DLBCL) of the head-and-neck area primarily involves the Waldeyer ring (WR) and sinonasal area (SN). However, the differential clinical outcomes between patients with WR-DLBCL and those with SN-DLBCL in the rituximab era remain unclear.

methodsTo avoid confounding factors contributed by advanced DLBCL with WR and SN involvement, we assessed the clinical outcomes of patients with stage I/II WR-DLBCL and SN-DLBCL and compared them with those having corresponding stages of DLBCL in the lymph nodes but without other extranodal involvement (LN-DLBCL) in the same period. We compared the patients' clinical characteristics, treatment modalities, event-free survival (EFS), and overall survival (OS) among the three subgroups.

resultsWe analyzed 67, 15, and 106 patients with WR-DLBCL, SN-DLBCL, and LN-DLBCL, respectively, between January 2000 and December 2019. All patients received front-line rituximab-based regimens, and > 80% received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone-based regimens. More patients with SN-DLBCL had revised International Prognostic Index (R-IPI) score 3 (27%) when compared with those with WR-DLBCL (7%) and those with LN-DLBCL (10%, p = 0.181). Patients with WR-DLBCL, LN-DLBCL, and SN-DLBCL had 5-year EFS and OS rates of 80.7%, 59.5%, and 41.9% (p = 0.021) and 83.7%, 70.8%, and 55.8% (p = 0.032), respectively. Compared to patients with LN-DLBCL, those with WR-DLBCL also had a significantly favorable 5-year EFS rate (p = 0.021) and 5-year OS rate (p = 0.023). Three of the 15 patients with SN-DLBCL experienced lymphoma recurrence in the brain after front-line treatment. In multivariate analyses, R-IPI scores of 1-2 and 3 served as significantly poor prognostic factors for patients with poor EFS and OS.

conclusionsCompared to patients with LN-DLBCL, patients with WR-DLBCL receiving front-line rituximab-based treatments had favorable clinical outcomes; however, patients with SN-DLBCL had worse clinical outcomes. Further studies on molecular prognostic factors and treatment strategies for SN-DLBCL are warranted.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseRituximabAdultAgedAged, 80 and overCyclophosphamideDoxorubicinFemaleHumansMaleMiddle AgedNeoplasm StagingParanasal Sinus NeoplasmsPrognosisRetrospective StudiesCyclophosphamideDoxorubicinRituximabVincristineDLBCLextranodalprognosisR‐IPI scoresinonasal areaTaiwanWaldeyer ring

Identifiers

PMID38148602
PMCPMC10807621
OpenAlexW4390272067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.